Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Leukocyte Adhesion Deficiency: later-stage trial registry
2 of 3 indexed Leukocyte Adhesion Deficiency trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Leukocyte Adhesion Deficiency: 3 US clinical trials tracked, 2 recruiting.
Leukocyte Adhesion Deficiency is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is AUG Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition leukocyte-adhesion-deficiency
OPEN 2 | RECR 67% | LATE 2 | EARLY 0 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Leukocyte Adhesion Deficiency lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Leukocyte Adhesion Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Leukocyte Adhesion Deficiency is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II
AUG Therapeutics
NCT05462587
An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II
AUG Therapeutics
NCT05754450
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals
NCT06282432
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Leukocyte Adhesion Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Leukocyte Adhesion Deficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Leukocyte Adhesion Deficiency page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Leukocyte Adhesion Deficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AUG Therapeutics sponsors the most Leukocyte Adhesion Deficiency trials on record, review their full trial history before evaluating a specific study. See AUG Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leukocyte Adhesion Deficiency condition card totals 3 registered trials; most-linked intervention AVTX-803 (L-Fucose); top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.